This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Ajou University Industry-Academic Cooperation Foundation. Active years: 2019-2021.
Location History:
- Seocheon-gun, KR (2019)
- Chungcheongnam-do, KR (2021)
Company Filing History:
Years Active: 2019-2021
Title: Gi Bang Koo: Innovator in Anticancer Research
Introduction
Gi Bang Koo is a prominent inventor based in Chungcheongnam-do, South Korea. He has made significant contributions to the field of anticancer research, focusing on innovative methods and compositions that enhance the effectiveness of cancer treatments. With a total of 2 patents, his work is paving the way for new therapeutic strategies.
Latest Patents
Gi Bang Koo's latest patents include a composition for an anticancer adjuvant that comprises a receptor-interacting protein kinase-3 (RIP3) expression promoter as an active ingredient. This invention also encompasses methods for screening anticancer adjuvants that promote RIP3 expression and enhance the sensitivity of anticancer agents. Additionally, he has developed a method for monitoring the sensitivity of anticancer agents based on RIP3 expression. His research indicates that pre-treating patients lacking RIP3 expression with a demethylating agent may improve the efficacy of conventional chemotherapeutic agents.
Career Highlights
Gi Bang Koo is affiliated with the Ajou University Industry-Academic Cooperation Foundation, where he continues to advance his research in anticancer therapies. His innovative approaches aim to improve patient outcomes through enhanced drug sensitivity and targeted treatment strategies.
Collaborations
He collaborates with notable colleagues, including You Sun Kim and Jung Ho Yun, to further his research initiatives and develop effective cancer treatment methodologies.
Conclusion
Gi Bang Koo's contributions to anticancer research exemplify the potential of innovative approaches in enhancing treatment efficacy. His work is crucial in the ongoing battle against cancer, offering hope for improved therapeutic strategies.